These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 762107)

  • 21. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
    Grant S; Rauscher F; Jakubowski A; Cadman E
    Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-copy and amplified CAD genes in Syrian hamster chromosomes localized by a highly sensitive method for in situ hybridization.
    Wahl GM; Vitto L; Padgett RA; Stark GR
    Mol Cell Biol; 1982 Mar; 2(3):308-19. PubMed ID: 6180304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC
    Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. General method for cloning amplified DNA by differential screening with genomic probes.
    Brison O; Ardeshir F; Stark GR
    Mol Cell Biol; 1982 May; 2(5):578-87. PubMed ID: 6896736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrimidine biosynthesis in Saccharomyces cerevisiae: the ura2 cluster gene, its multifunctional enzyme product, and other structural or regulatory genes involved in de novo UMP synthesis.
    Denis-Duphil M
    Biochem Cell Biol; 1989 Sep; 67(9):612-31. PubMed ID: 2679804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
    Karle JM; Anderson LW; Dietrick DD; Cysyk RL
    Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C
    Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. m-AMSA and PALA: two new agents in cancer chemotherapy.
    Rozencweig M; Von Hoff DD; Cysyk RL; Muggia FM
    Cancer Chemother Pharmacol; 1979; 3(3):135-41. PubMed ID: 393427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
    Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
    Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
    Baillon J; Guichard M; Malaise EP; Hervé G
    Cancer Res; 1983 May; 43(5):2277-82. PubMed ID: 6831451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J; Moore EC; Hall SW; Loo TL
    Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
    Kensler TW; Jayaram HN; Cooney DA
    Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A; Anderson LW; Strong J; Cysyk RL
    J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stable mutants of mammalian cells that overproduce the first three enzymes of pyrimidine nucleotide biosynthesis.
    Kempe TD; Swyryd EA; Bruist M; Stark GR
    Cell; 1976 Dec; 9(4 Pt 1):541-50. PubMed ID: 12870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic resistance to methotrexate and N-phosphonacetyl L-aspartate is induced by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA).
    Kinsella AR; Fox M
    Int J Cancer; 1988 Jul; 42(1):87-93. PubMed ID: 3391708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability.
    Cillo C; Ling V; Hill RP
    Int J Cancer; 1989 Jan; 43(1):107-11. PubMed ID: 2910823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis.
    Jones ME
    Annu Rev Biochem; 1980; 49():253-79. PubMed ID: 6105839
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of N-phosphonacetyl-L-aspartate and D-glucosamine on the incorporation of 5-fluorouridine into normal tissues and an adenocarcinoma in the rat.
    Erichsen C; Christensson PI; Jakobsson B; Eriksson G; Yngner T; Jönsson PE; Stenram U
    Anticancer Res; 1987; 7(1):77-80. PubMed ID: 3566186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cloning and reintroduction into animal cells of a functional CAD gene, a dominant amplifiable genetic marker.
    de Saint Vincent BR; Delbrück S; Eckhart W; Meinkoth J; Vitto L; Wahl G
    Cell; 1981 Dec; 27(2 Pt 1):267-77. PubMed ID: 6277500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.